0001209191-21-057703.txt : 20210924
0001209191-21-057703.hdr.sgml : 20210924
20210924181337
ACCESSION NUMBER: 0001209191-21-057703
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210922
FILED AS OF DATE: 20210924
DATE AS OF CHANGE: 20210924
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CHESS ROBERT
CENTRAL INDEX KEY: 0001227886
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24006
FILM NUMBER: 211278482
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS
CENTRAL INDEX KEY: 0000906709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943134940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 4154825300
MAIL ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC
DATE OF NAME CHANGE: 19980723
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS
DATE OF NAME CHANGE: 19940303
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-09-22
0
0000906709
NEKTAR THERAPEUTICS
NKTR
0001227886
CHESS ROBERT
C/O NEKTAR THERAPEUTICS
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO
CA
94158
1
0
0
0
Common Stock
2021-09-22
4
A
0
10200
0.00
A
284473
D
Common Stock
2021-09-22
4
S
0
4600
17.94
D
279873
D
Common Stock
2100
I
by daughter
Common Stock
2100
I
by son
Common Stock
2100
I
by daughter
Stock Option
17.78
2021-09-22
4
A
0
20400
0.00
A
2029-09-21
Common Stock
20400
20400
D
Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
This RSU award vests in full, one year following September 22, 2021.
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This transaction was executed in multiple trades at prices ranging from $17.59 to $18.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issues.
The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2021.
Mark A. Wilson, Attorney-in-Fact
2021-09-24